Literature DB >> 16905026

Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?

Arlan L Rosenbloom1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905026     DOI: 10.1016/S0140-6736(06)69205-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Growth hormone and health policy.

Authors:  Leona Cuttler; J B Silvers
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

2.  Elbow loading promotes longitudinal bone growth of the ulna and the humerus.

Authors:  Ping Zhang; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2011-07-06       Impact factor: 2.626

Review 3.  Short and tall stature: a new paradigm emerges.

Authors:  Jeffrey Baron; Lars Sävendahl; Francesco De Luca; Andrew Dauber; Moshe Phillip; Jan M Wit; Ola Nilsson
Journal:  Nat Rev Endocrinol       Date:  2015-10-06       Impact factor: 43.330

Review 4.  Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?

Authors:  Bharti Balhara; Madhusmita Misra; Lynne L Levitsky
Journal:  Indian J Pediatr       Date:  2011-11-17       Impact factor: 1.967

5.  Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38].

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-08

Review 6.  Treatment of children and adolescents with idiopathic short stature.

Authors:  Michael B Ranke
Journal:  Nat Rev Endocrinol       Date:  2013-04-23       Impact factor: 43.330

7.  Idiopathic short stature: conundrums of definition and treatment.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2009-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.